The 1^st line agents for the management of schizophrenia are the Second-Generation Antipsychotics (SGAs) due to the superior efficacy in comparison to First-Generation typical antipsychotics. Associated with metabolic disturbances. People with schizophrenia have an excess mortality, 2 to 3 times higher than the general population and is primarily associated with metabolic disturbances and poor adherence to the therapy. Diabetic ketoacidosis (DKA) is a rare, but potentially fatal hyperglycemic emergency from dysregulated acute glucose metabolism, which may be associated with the use of SGAs. We report a case of 63-year-old Females chizophrenic patient who presented with DKA along with metabolic abnormalities from antipsychotic poly-pharmacy.